Opportunities for transnational and translational R&D was the title of a paper for this Journal's readers in 2005 (when it was still South African Psychiatry Review). It was intended to encourage exploring opportunities for collaborative research. 1 So what has evolved? Here are some examples of what has been accomplished, and what is in the pipeline of psychiatric collaboration between South Africa (SA), Uganda, and Europe. My intention was not to approach this a a neo-colonialist, rather to stress what I believe to be mutually beneficial projects, emanating from the needs of the African psychiatric patient in various settings.
To move forward from the consequences of the academic boycott during the apartheid years, new friendships needed to be established. 4 Five or more SA researchers have now benefited from this program in visiting Leiden University, University of Tartu, University of Hertfordshire/University of Cambridge, the University of Göttingen, and the University of Southampton. These projects have dealt with social anxiety and depression in alcohol use disorders, cognitive and emotional dysfunction in Cushing's syndrome, proteomics in the biobank of a prospective cohort, MRI findings in alcohol use disorder with and without anxiety, Opportunities for transnational and translational research in Europe and neurocognitive function in OCD patients.
Future researchers looking for grants can monitor Horizon 2020, the umbrella name for research coordination and funding by the European Union. The program is expected to be budgeted and launched in January 2014 (http://ec.europa.eu/research/horizon2020/index_en.cfm? pg=home&video=none). This source is something to look out for to fund collaborative research that has great promise to be mutually beneficial.
In conclusion, several psychiatric research collaborations have been established since the academic boycott during the apartheid years. This came about because of efforts by European as well as African psychiatrists in both SA and Uganda. In addition, there have been numerous presentations by distinguished SA psychiatrists at international meetings that I have not mentioned in this commentary, book editions, electives for undergraduate nursing and medical students, and personal transnational friendships. Pharmaceutical drug development has built on multicenter studies of both SA and European centers. Within the African context South Africa is now part of the international community of academic psychiatric research for the benefit of all parties.
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